Sciele Pharma, Inc. Announces Successful Completion of New Sular Formulation Clinical Trial Program

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced the successful completion of the clinical trial program for its new Sular formulation. The study results showed that the new Sular formulation is bioequivalent to Sciele’s currently marketed Sular. The new Sular formulation utilizes SkyePharma’s (LSE:SKP) patented Geomatrix™ technology, which is designed to provide a lower dose of Sular for each of its current doses.

Back to news